Blab Tech
Trump Administration Cuts $5 Billion in U.S. Research Funding, Threatening Medical and Technological Progress
When the Trump administration froze or terminated more than 5,300 federal research grants in November 2025, it set the nation’s scientific future on hold. The cuts cut across the two biggest federal backers of basic research, totaling a staggering $5 billion—$2.3 billion from the National Institutes of Health (NIH) and $700 million from the National Science Foundation (NSF). Scientists, lawmakers, and the public have all voiced alarm.
The NIH, headquartered in Bethesda, Maryland, is the nation’s largest supporter of biomedical research. Its extramural program—funding work carried out in universities—has historically accounted for roughly 28 % of all U.S. biomedical spending, about $26.4 billion a year in 2025. The NSF, an independent agency, funds fundamental research and education in science and engineering disciplines that fall outside the NIH’s remit. Together, the two agencies drive the majority of the United States’ basic research.
MIT President Sally Kornbluth warned that the cuts threaten the very foundation of modern technology. "Anything you see in everyday life that has a scientific or technological bent began as basic research, just scientists trying to understand," she said. "And almost all of that research in this country is done in universities." She added that the effects will ripple over the next decade, erasing medical advances and new technologies.
NIH cuts have been especially harsh. In early 2025 the administration froze key NIH operations, and by January 2026 about 2,600 grants—worth $1.4 billion—remained suspended, though some were later reinstated by court orders. The agency also cut the rate at which it pays for indirect costs, squeezing university research budgets. NPR coverage reports that roughly 1,200 NIH staff members were laid off as a result of the freeze, and research on LGBTQ health—an area that had received heightened federal support under the previous administration—was halted.
The NSF has faced a parallel wave of reductions. Since early April 2025, it has canceled more than 1,500 grants and contracts totaling over $1 billion, according to the Urban Institute. The cuts disproportionately affected diversity, equity and inclusion projects; nearly 90 % of the canceled grants fell in that category. Despite the reductions, the NSF’s new grant count fell by 20 % but the average size of new grants increased, a trend noted by Science News.
The fallout extends beyond lost dollars. The NIH estimates that every $100 million in funding generates 76 patents and $598 million in downstream research and development. A 2025 AmericanScience.org report warned that the NIH’s cuts could lead to a significant decline in patent output and subsequent innovation. Women researchers, who already face funding disparities, have been hit particularly hard; a 2025 analysis found that the NIH terminated almost 2,300 active grants worth $2.45 billion, disproportionately affecting early‑career women scientists.
Congressional leaders have responded to the cuts. In March 2025 a Boston city council resolution condemned the reductions, citing their potential harm to the city’s research institutions and economy. In February 2026 Senators Markey and Warren requested clarification from the NIH on the status of the suspended grants, and a Senate committee held a hearing on the broader implications of the administration’s science policy.
The situation remains fluid. Court orders have reinstated some NIH grants, and the NSF has announced plans to adjust its funding strategy to mitigate the impact on research projects. Yet the long‑term effects on medical breakthroughs, technology development and the U.S. research workforce remain uncertain. The federal government’s continued stance on research funding will likely shape the trajectory of U.S. innovation for years to come.
The NIH, headquartered in Bethesda, Maryland, is the nation’s largest supporter of biomedical research. Its extramural program—funding work carried out in universities—has historically accounted for roughly 28 % of all U.S. biomedical spending, about $26.4 billion a year in 2025. The NSF, an independent agency, funds fundamental research and education in science and engineering disciplines that fall outside the NIH’s remit. Together, the two agencies drive the majority of the United States’ basic research.
MIT President Sally Kornbluth warned that the cuts threaten the very foundation of modern technology. "Anything you see in everyday life that has a scientific or technological bent began as basic research, just scientists trying to understand," she said. "And almost all of that research in this country is done in universities." She added that the effects will ripple over the next decade, erasing medical advances and new technologies.
NIH cuts have been especially harsh. In early 2025 the administration froze key NIH operations, and by January 2026 about 2,600 grants—worth $1.4 billion—remained suspended, though some were later reinstated by court orders. The agency also cut the rate at which it pays for indirect costs, squeezing university research budgets. NPR coverage reports that roughly 1,200 NIH staff members were laid off as a result of the freeze, and research on LGBTQ health—an area that had received heightened federal support under the previous administration—was halted.
The NSF has faced a parallel wave of reductions. Since early April 2025, it has canceled more than 1,500 grants and contracts totaling over $1 billion, according to the Urban Institute. The cuts disproportionately affected diversity, equity and inclusion projects; nearly 90 % of the canceled grants fell in that category. Despite the reductions, the NSF’s new grant count fell by 20 % but the average size of new grants increased, a trend noted by Science News.
The fallout extends beyond lost dollars. The NIH estimates that every $100 million in funding generates 76 patents and $598 million in downstream research and development. A 2025 AmericanScience.org report warned that the NIH’s cuts could lead to a significant decline in patent output and subsequent innovation. Women researchers, who already face funding disparities, have been hit particularly hard; a 2025 analysis found that the NIH terminated almost 2,300 active grants worth $2.45 billion, disproportionately affecting early‑career women scientists.
Congressional leaders have responded to the cuts. In March 2025 a Boston city council resolution condemned the reductions, citing their potential harm to the city’s research institutions and economy. In February 2026 Senators Markey and Warren requested clarification from the NIH on the status of the suspended grants, and a Senate committee held a hearing on the broader implications of the administration’s science policy.
The situation remains fluid. Court orders have reinstated some NIH grants, and the NSF has announced plans to adjust its funding strategy to mitigate the impact on research projects. Yet the long‑term effects on medical breakthroughs, technology development and the U.S. research workforce remain uncertain. The federal government’s continued stance on research funding will likely shape the trajectory of U.S. innovation for years to come.
